TWi Biotechnology, a subsidiary of Taiwan’s TWi Pharmaceuticals, has received permission to begin a Taiwan-US Phase II trial of a novel treatment for gout and high blood uric acid levels. Both the US and Taiwan FDAs approved a protocol for the trial, which will test TWi’s AC-201 controlled-release oral formulation of an Interleukin-1Beta inhibitor. TWi has already successfully completed a US-Taiwan Phase II trial of AC-201 among patients with type 2 diabetes.
Help employers find you! Check out all the jobs and post your resume.
